These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 36514282)

  • 1. Ponesimod: An Oral Second-Generation Selective Sphingosine 1-Phosphate Receptor Modulator for the Treatment of Multiple Sclerosis.
    Alnaif A; Oiler I; D'Souza MS
    Ann Pharmacother; 2023 Aug; 57(8):956-965. PubMed ID: 36514282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Efficacy of Relapsing Multiple Sclerosis Therapies: Model-Based Meta-Analyses for Confirmed Disability Accumulation and Annualized Relapse Rate.
    Hennessy B; Zierhut ML; Kracker H; Keenan A; Sidorenko T
    Mult Scler Relat Disord; 2022 Aug; 64():103908. PubMed ID: 35803162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial.
    Kappos L; Fox RJ; Burcklen M; Freedman MS; Havrdová EK; Hennessy B; Hohlfeld R; Lublin F; Montalban X; Pozzilli C; Scherz T; D'Ambrosio D; Linscheid P; Vaclavkova A; Pirozek-Lawniczek M; Kracker H; Sprenger T
    JAMA Neurol; 2021 May; 78(5):558-567. PubMed ID: 33779698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ponesimod in the Treatment of Relapsing Forms of Multiple Sclerosis: An Update on the Emerging Clinical Data.
    Ruggieri S; Quartuccio ME; Prosperini L
    Degener Neurol Neuromuscul Dis; 2022; 12():61-73. PubMed ID: 35356493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ponesimod for the treatment of relapsing multiple sclerosis.
    Baldin E; Lugaresi A
    Expert Opin Pharmacother; 2020 Nov; 21(16):1955-1964. PubMed ID: 32808832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sphingosine 1-Phosphate Receptor Modulators for Multiple Sclerosis.
    Roy R; Alotaibi AA; Freedman MS
    CNS Drugs; 2021 Apr; 35(4):385-402. PubMed ID: 33797705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy and safety of ozanimod and ponesimod for relapsing multiple sclerosis: A matching-adjusted indirect comparison.
    Swallow E; Pham T; Patterson-Lomba O; Yin L; Gomez-Lievano A; Liu J; Tencer T; Gupte-Singh K
    Mult Scler Relat Disord; 2023 Mar; 71():104551. PubMed ID: 36791623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative safety of high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.
    Śladowska K; Kawalec P; Holko P; Osiecka O
    Neurol Sci; 2022 Sep; 43(9):5479-5500. PubMed ID: 35713731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ponesimod, a selective S1P1 receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseases.
    D'Ambrosio D; Freedman MS; Prinz J
    Ther Adv Chronic Dis; 2016 Jan; 7(1):18-33. PubMed ID: 26770667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Teriflunomide for multiple sclerosis.
    He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
    Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis.
    Dumitrescu L; Papathanasiou A; Coclitu C; Garjani A; Evangelou N; Constantinescu CS; Popescu BO; Tanasescu R
    Expert Opin Pharmacother; 2023 Mar; 24(4):495-509. PubMed ID: 36946625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term Treatment With Ponesimod in Relapsing-Remitting Multiple Sclerosis: Results From Randomized Phase 2b Core and Extension Studies.
    Freedman MS; Pozzilli C; Havrdova EK; Lemle A; Burcklen M; Larbalestier A; Hennessy B; Sidorenko T; Vaclavkova A; Olsson T;
    Neurology; 2022 Aug; 99(8):e762-e774. PubMed ID: 35667837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Teriflunomide for multiple sclerosis.
    He D; Zhang C; Zhao X; Zhang Y; Dai Q; Li Y; Chu L
    Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009882. PubMed ID: 27003123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic Potential of Ponesimod Alone and in Combination with Dimethyl Fumarate in Experimental Models of Multiple Sclerosis.
    Pouzol L; Piali L; Bernard CC; Martinic MM; Steiner B; Clozel M
    Innov Clin Neurosci; 2019 Mar; 16(3-4):22-30. PubMed ID: 31214480
    [No Abstract]   [Full Text] [Related]  

  • 15. Ponesimod to treat multiple sclerosis.
    Ianniello A; Pozzilli C
    Drugs Today (Barc); 2021 Dec; 57(12):745-758. PubMed ID: 34909803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial.
    Olsson T; Boster A; Fernández Ó; Freedman MS; Pozzilli C; Bach D; Berkani O; Mueller MS; Sidorenko T; Radue EW; Melanson M
    J Neurol Neurosurg Psychiatry; 2014 Nov; 85(11):1198-208. PubMed ID: 24659797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab for relapsing-remitting multiple sclerosis.
    He D; Guo R; Zhang F; Zhang C; Dong S; Zhou H
    Cochrane Database Syst Rev; 2013 Dec; (12):CD009130. PubMed ID: 24310855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing-Remitting Multiple Sclerosis.
    Freeman L; Longbrake EE; Coyle PK; Hendin B; Vollmer T
    CNS Drugs; 2022 Dec; 36(12):1285-1299. PubMed ID: 36350491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ponesimod inhibits astrocyte-mediated neuroinflammation and protects against cingulum demyelination via S1P
    Kihara Y; Jonnalagadda D; Zhu Y; Ray M; Ngo T; Palmer C; Rivera R; Chun J
    FASEB J; 2022 Feb; 36(2):e22132. PubMed ID: 34986275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
    Wingerchuk DM; Carter JL
    Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.